You are here
Interferon beta-1a for multiple sclerosis: old drug, new clothes
The Lancet Neruology, Volume 13, Issue 7, July 2014, Pages 638–639
The development of new drugs for treatment of relapsing-remitting multiple sclerosis has been extremely successful. The oral drugs dimethylfumarate and teriflunomide and the monoclonal antibody alemtuzumab have enlarged the therapeutic armamentarium, which is presently composed of ten approved drugs.1 and 2 In The Lancet Neurology, Peter Calabresi and colleagues report the 48-week results of a phase 3 trial (ADVANCE) 3of an old drug in a new formulation: pegylated interferon beta-1a.